Patients’ Preferred Endpoints May Not Satisfy Regulatory Needs, US FDA Says
Executive Summary
Just because a measure is relevant to the patient community does not mean it is capable of capturing meaningful change in a clinical trial, US FDA officials say at a meeting on mitochondrial disease drug development.
You may also be interested in...
Mitochondrial Disease Workshop Shows US FDA Commitment To First Approvals
First FDA-hosted workshop on rare family of mitochondrial diseases offers plenty of opportunities to talk challenges in R&D – and identify some solutions.
Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.
US FDA Divided On Expanded Access Requests For Off-Label Use Of Approved Drugs
Agency’s clinical experts favor granting access under regulations intended for investigational drugs but ‘lawyers want consistency under the law,’ FDA’s Woodcock says; use of the expanded access pathway for approved agents is generally unnecessary but may provide sponsors with some regulatory cover, external experts say.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: